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Abstract
Biochemical cellular targets and more general metabolic processes in cancer cells can be visualised. Extensive data
are available on molecular imaging in preclinical models. However, innovative tracers move slowly to the clinic.
This review provides information on the currently available methods of metabolic imaging, especially using PET
in humans. The uptake mechanisms of tracer methods and a brief discussion of the more ‘molecular’ targeted
methods are presented. The main focus is on the different classes of tracers and their application in various types
of cancer within each class of tracers, based on the current literature and our own experience. Studies with [18F]FDG
(energy metabolism), radiolabelled amino acids (protein metabolism), [18F]FLT (DNA metabolism), [11C]choline
(cell membrane metabolism) as general metabolic tracer methods and [18F]DOPA (biogenic amine metabolism) as a
more specific tracer method are discussed. As an example, molecular imaging methods that target the HER2 receptor
and somatostatin receptor are described.
Keywords: Molecular imaging; oncology.
Introduction
Several modalities can be used in humans for molecular
imaging, such as single photon emission computed
tomography (SPECT), positron emission tomography
(PET), magnetic resonance imaging (MRI) and computed
tomography (CT). The combination of the increasing
availability of PET and conventional nuclear medicine
imaging methods fused with CT/MRI for precise
anatomical localisation, the discovery of a multitude of
new targets, and rationally designed drugs in oncology,
have led to a tremendous interest in molecular imaging
in oncology. Nuclear medicine imaging methods use
tracers that target specific mechanisms in cancer cells
and tissues. Depending on the properties of the tracers,
various aspects of cancer cells can be targeted and
visualised. These methods can be used in staging and
restaging of cancer patients, evaluation and prediction
of treatment response, and may contribute to the
determination of the prognosis of patients. Also in the
characterisation of lesions, the domain of pathological
evaluation, imaging methods may contribute to oncology,
as they permit total body imaging in a non-invasive
way. The new anti-cancer drugs, consisting of both small
(e.g. tyrosine kinase inhibitors) or large molecules (e.g.
monoclonal antibodies), can often be radiolabelled and
molecular imaging methods may generate information
on biodistribution, metabolism and treatment induced
changes in the targets of these drugs. The process of
developing specific tracers, however, is laborious and,
after radiochemical production, extensive evaluation is
required before they can be used clinically.
Apart from the increasing interest in specific bio-
chemical targets, currently available molecular imaging
methods target more general metabolic processes in
cancer cells. Among all the targets for imaging that
are theoretically present during oncogenesis, imaging of
metabolic targets is generally called ‘metabolic imaging’,
whereas methods aimed at more specific biochemical
targets could be regarded as ‘molecular imaging’.
However, the precise definition of these terms is rather
subjective.
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The general principles of nuclear medicine imaging
also apply to molecular imaging. These include knowl-
edge of the normal distribution of a tumour tracer that
determines in what regions of the body the method may
be successful. For example, high background uptake
in an organ may interfere with tumour visualisation in
that organ. Another main factor is the level of uptake.
Visualisation depends on the detecting system (PET
camera, gamma camera), but also strongly on the amount
of tracer that is present at or in the target. In theory, a sub-
millimetre lesion can be detected, as long as tracer uptake
is high enough. On the other hand, a large lesion may
be missed when the uptake level is too low. In contrast
with radiological methods, it is therefore in principle not
possible to determine a detection threshold, although in
daily practice this threshold is generally around 0.5–1 cm
for the best methods.
Extensive data are available on molecular imaging
in preclinical models. The main aim of this review
is to provide information on the currently available
methods for metabolic imaging, especially with regard
to PET in humans. A special focus is placed on
the uptake mechanisms of tracer methods, as this
is critical in understanding the images. Finally, a
brief discussion of the more ‘molecular’ targeted
methods is presented. The main focus is on the
different classes of tracers, describing applications in
various types of cancer within each class of tracers,
based on the current literature and our own experi-
ence. We discuss [18F]fluorodeoxyglucose ([18F]FDG,
energy metabolism), radiolabelled amino acids (pro-
tein metabolism), [18F]fluorothymidine ([18F]FLT, DNA
metabolism), [11C]choline (cell membrane metabolism)
as general metabolic tracer methods, and [18F]DOPA
(biogenic amine metabolism) as a more specific tracer
method. As an example of molecular imaging, we
describe methods that target the HER2 receptor.
[18F]FDG: energy metabolism
It has long been known that tumours contain large quan-
tities of lactic acid, because they rely on anaerobic gly-
colysis for a major part of their energy consumption [1].
This is a relatively inefficient process, since anaerobic
glycolysis generates only a limited amount of energy
(ATP) per molecule of glucose. This inefficient use of
‘fuel’ results in a strongly increased demand for glucose
in cancer cells. Generally, tumour cells have upregulated
all the mechanisms that are necessary to obtain glucose,
such as the GLUT1 transmembrane transporter and
intracellular enzymes such as hexokinase [2]. This is the
uptake principle of the [18F]FDG tracer that is a direct
analogue of glucose. The strongly increased uptake of
FDG in cancer cells contrasts with most normal cells and
organs. In addition, once FDG has entered the cell, it is
phosphorylated but, unlike glucose itself, it is not further
metabolised. This intracellular trapping, in combination
with the relatively high resolution of PET cameras,
leads to adequate detection properties of tumours and
metastases, provided they are metabolically active.
Normal distribution of FDG includes high uptake
in the brain, especially in the grey matter, and in
the kidneys and bladder, because of renal clearance.
Moderate background uptake is generally present in the
liver, muscles, small intestine and bone marrow, but
this background uptake is (sufficiently) low to permit
visualisation of tumour lesions.
Many clinical applications have emerged over recent
years and because of the rapidly expanding availability
of this technique, the list is growing steadily. Among the
widely accepted indications are staging and/or restaging
of non-small cell lung cancer [3], malignant lymphoma,
head-and-neck cancer, colorectal cancer, oesophageal
cancer [4], melanoma, and thyroid cancer. In each type
of cancer the precise role of [18F]FDG PET depends
on the properties of the tumour and the possibilities of
other diagnostic modalities. Recently, the Food and Drug
Administration in the USA has generalised the accepted
indications for PET, instead of the detailed list of
separate indications that existed before [5]. [18F]FDG PET
is now approved ‘for assessment of abnormal glucose
metabolism to assist in the evaluation of malignancy in
patients with known or suspected abnormalities found by
other testing modalities, or in patients with an existing
diagnosis of cancer’ [5].
[18F]FDG PET can be of interest to follow the
effects of new types of treatment. The best exam-
ple of this application is response evaluation of the
signal transduction inhibitor imatinib (Glivec). This
biochemically engineered drug appears to shut down
the energy metabolism in gastro-intestinal stroma cell
tumours, almost immediately after the start of treatment.
While morphological imaging does not show changes,
[18F]FDG PET demonstrates a dramatic decrease in
metabolic rate, which appears helpful in the early
identification of responders [6,7]. The EORTC-PET Group
has established response assessment guidelines for
PET [8]. A major new development in molecular imaging
is the development of image fusion methods, such as
PET-CT scanners or PET-CT/MRI fusing software. These
new methods combine the precise anatomical information
of CT/MRI with the metabolic information from PET. In
this way, accurate localisation of PET lesions becomes
possible and the interpretation of both PET and CT scans
improves [9]. In addition to PET-CT, simulator hardware
integrated with innovative software for radiotherapy
planning assisted by [18F]FDG PET imaging is currently
under study.
The drawbacks of FDG include uptake by inflam-
matory tissues and cells, which may interfere with
oncological imaging [10]. In general, positive PET find-
ings require cytological or histological confirmation.
In the assessment of brain tumours and metastases,
[18F]FDG PET is difficult because of high background
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uptake. Finally, some tumours, such as low-grade
sarcoma or prostate cancer, have a low uptake of FDG,
which precludes successful imaging. For prostate cancer,
the proximity of the bladder further interferes with
imaging.
Radiolabelled amino acids: protein
metabolism
Synthesis of proteins is a fundamental process for all
cellular functions. Because of the uncontrolled and
accelerated growth of cancer, the process of protein
synthesis in tumours is increased. As a consequence, the
demand for amino acids, the building blocks of proteins,
is increased. Therefore, it is expected that radiolabelled
amino acid tracers will also accumulate in tumours,
and subsequent imaging of the amino acid metabolism
could provide useful information with regard to tumour
metabolism. Nearly all amino acids and slightly modified
variants have been radiolabelled, but only a few have
passed the prerequisites (reliable production, stability
in vivo, adequate tumour uptake) to a degree sufficient
for use clinically. Among these few are [11C]methionine
(MET), [11C]tyrosine (TYR), [18F]fluorethyl-tyrosine
(FET) for PET imaging, and [123I]iodomethyl-tyrosine
(IMT) for SPECT imaging [11].
To understand how cellular processes are actually
represented on the images obtained after administration
of amino acid tracers, extensive preclinical research has
been performed. Protein metabolism can be divided into
amino acid transport (from plasma into the cell) and
protein synthesis (incorporation in protein). IMT uptake
appears to represent the increased transport into tumour
cells, TYR uptake represents both transport and protein
synthesis, and MET uptake represents transport, but
partly also protein synthesis and other cellular processes.
It appears, however, that these differences do not translate
into different clinical applicability. Amino acid imaging
is less influenced by inflammation, which is advantageous
in comparison with FDG PET imaging. However, also for
amino acids, tumour specificity is not perfect [12].
In brain tumour imaging, the use of radiolabelled
amino acids is quite well established since [18F]FDG
PET does not perform well here. Applications include
tumour grading, delineation, evaluation of treatment
response, and recurrence detection. Diagnostic accuracy
of amino acid imaging in brain tumours is adequate, and
probably has advantageous diagnostic value. However,
the true therapeutic value and value for the prediction
of final patient outcome still needs to be established. In
other tumours, such as head-and-neck or lung cancer,
findings suggest reasonable diagnostic accuracy, but
inferior diagnostic value in comparison with [18F]FDG
PET [13]. In most other tumours, the data do not permit
definitive conclusions yet, but the general feasibility of
amino acid imaging has been sufficiently demonstrated.
In nearly all tumour types more research is required in
larger patient series and in well-defined clinical settings.
[18F]FLT: DNA metabolism
In recent years [18F]FLT has attracted much attention, as
the end result of a long search for a tracer, the uptake of
which would accurately reflect DNA synthesis [13]. This,
in turn, would directly reflect the tumour proliferation
status, which would be clinically helpful, for instance
in response assessment. Theoretically FLT may be less
dependent on interference from inflammatory cells, as
compared to FDG. The uptake mechanism of FLT is
now clear. FLT is transported across cell membranes by
nucleoside transporter proteins. Once intracellular, FLT
is phosphorylated by thymidine kinase I. Comparable to
FDG, the phosphorylated tracer is trapped intracellularly,
but is not further metabolised into DNA. It is important
to realise that there are two main pathways involved in
DNA synthesis. The exogenous or ‘salvage’ pathway,
which utilises precursors from outside the cell that are
phosphorylated by TK1, and the endogenous pathway, in
which intracellular molecules, such as uridine monophos-
phate, enter DNA synthesis after phosphorylation by
thymidylate synthase. The uptake of FLT appears to be
a measure of the activity of the salvage pathway, and
therefore depends on the activity of TK1. In general,
TK1 is approximately 10-fold increased in cancer cells,
especially during the S phase of the cell cycle [14].
It has now been demonstrated in many types of
cancer, that FLT uptake in vivo is a measure of
tumour proliferation activity. In addition, in in vitro and
animal studies comparing FDG and FLT have repeatedly
confirmed that FLT uptake in inflammatory tissue is
considerably less than FDG, which is advantageous.
However, uptake in tumour tissue itself appears to be
lower than FDG, as has been demonstrated in many
types of cancer [14]. Since high uptake is among the
principle requirements of any successful imaging method
(especially when applied in cancer staging), this is an
important drawback. FLT PET, therefore, seems less
suitable for staging of cancer, and currently most research
focuses on response evaluation.
In FLT based response evaluation one has to keep
in mind that FLT uptake is a measure of the salvage
pathway of DNA synthesis. For example, cytostatic
agents that effectively cause arrest of the cell cycle in
the S-phase, such as 5-fluorouracil or methotrexate, lead
to an increase in FLT uptake. Similarly, agents that
block the endogenous pathway, such as gemcitabine,
lead to overactivity of the salvage pathway, and with
that, FLT uptake increases. Agents such as cisplatin or
doxorubicin, however, inhibit both pathways and as a
result decrease FLT uptake. These cellular effects have
been demonstrated in vitro in cell cultures and may be
temporary and different in vivo. Indeed, in vivo imaging
in animals has demonstrated that FLT tumour uptake
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declines rather rapidly (days to weeks), after various
forms of anti-tumour treatment.
Therefore, [18F]FLT PET imaging currently has no
accepted clinical indication, but its attractive uptake
mechanism, minor uptake in inflamed tissue and strong
association with proliferation activity may lead to
valuable applications in response-assessment [15].
Choline based tracers: membrane
metabolism
Choline is an important precursor in the synthesis of cell
membranes. As choline can be radiolabelled simply with
carbon-11, the idea of using [11C]choline for imaging of
cancer is obvious, since dividing cells require building
blocks for membranes. Various tracers derived from
choline have recently emerged and are currently being
tested. The most used variant, [11C]choline is chemically
identical to choline. However, fluorine-18 variants also
exist [16].
The uptake of choline appears to be driven by the
activity of choline kinase, which is generally increased
in tumour cells. Choline is intracellularly phosphorylated
and subsequently enters phospholipid synthesis path-
ways. High levels of choline and its metabolites have
long been known from magnetic resonance spectroscopy
imaging.
The normal appearance of a choline PET scan includes
high uptake in the liver and minor uptake in bone marrow
and intestinal tissues. The pancreas may also be visible,
as pancreatic juice contains phosphatidyl cholines. An
important advantage, compared to FDG, is the virtual
absence of bladder activity, since choline is not cleared
by the kidneys. Although choline can be considered
a general tumour tracer, it appears to be taken up
by prostate tissue in particular. The precise metabolic
background is not fully clear, but this property, combined
with the absence of bladder activity, has led to increasing
application of choline PET imaging in prostate cancer
staging and restaging, which is still notoriously difficult
with the diagnostic methods currently available.
Choline uptake in prostate cancer is clearly higher
than in normal and hypertrophic prostate tissue, although
some overlap exists. Primary tumours can therefore be
visualised, next to lymph node metastases [17–19]. As
application of this technique is still in its infancy, it is
too early to define the precise role. It is evident that
general uptake of choline in tumour lesions is lower
than FDG in FDG-avid types of cancer, which requires
a higher detection threshold [19]. An important clinical
problem is to find a substrate in the case of biochemical
recurrence after previous radical treatment of prostate
cancer. Current studies have demonstrated that choline
PET is able to detect recurrence at PSA values around
5–10 [20]. To select patients for salvage radiotherapy,
however, a lower PSA limit is required. Especially
in the field of prostate cancer imaging, an important
contribution is expected from combined PET-CT, as the
lower uptake of this tracer makes the separation of true
lesions from background activity (‘noise’) difficult. CT
can help in this regard.
Choline has also been applied in other types of cancer.
In brain tumours, similar to FLT and amino acids,
tumours can be visualised. In other types, such as lung
cancer and oesophageal cancer, it has been demonstrated
that choline PET is inferior to [18F]FDG PET for staging
purposes [21].
Somatostatin receptor imaging and
[18F]DOPA
Standard imaging of neuroendocrine gastrointestinal
tumours consists, among other diagnostics, of somato-
statin SPECT scanning. This scan can visualise somato-
statin receptors on the tumour cell membrane [22].
Neuroendocrine tumours are also characterised by the
ability to take up decarboxylate and accumulate amine
precursors. Aromatic-5-amino acid decarboxylase is the
key enzyme in this decarboxylation process and is
involved in both serotonin and catecholamine synthesis.
Other catecholamine synthesising enzymes have been
shown to be present in carcinoid tumours. These findings
have led to the use of [11C]DOPA and [18F]DOPA in rel-
atively small studies for the detection of neuroendocrine
tumours [23–25]. We performed a study with whole body
PET, after injection of 100–200 MBq [18F]DOPA and
oral pre-treatment with carbidopa in patients with neu-
roendocrine tumours. CT and somatostatin scanning were
performed within a short interval of tracer injection, using
standard methods. Endpoints were the number of patients
with positive tracer uptake, positive body regions (num-
ber of body regions with positive tracer uptake and the
number of individual lesions with positive tracer uptake).
Image interpretation of PET was blinded from other
imaging studies. For precise localisation PET-CT image
fusion was carried out. Newly detected lesions on PET
were validated using conventional methods when feasi-
ble. This ongoing study includes 36 patients (19 males
and 17 females). The [18F]DOPA PET scan was positive
in 35 of 36 patients (sensitivity 97%), and detected a
mean of 45 lesions per patient. CT was positive in 31 of
35 patients (sensitivity 88%), with a mean of 39 lesions
detected per patient Somatostatin scintigraphy was posi-
tive in 27 of 33 patients (sensitivity 82%) with 27 lesions
detected per patient. The largest numbers of lesions were
observed in the liver, with 1251 lesions for [18F]DOPA,
999 for CT and 541 for the somatostatin scans. In the
extrahepatic abdomen, we found 138/23/43, and in the
pelvic region 54/20/10 lesions, for the three techniques,
respectively. In 15 out of 26 patients, software fusion
of [18F]DOPA PET and CT was performed and led to a
better localisation of lesions. [18F]DOPA PET was clearly
Keynote lecture S31
superior to CT and somatostatin scintigraphy for staging
of neuroendocrine tumours. In addition, software-based
image fusion improved localisation of tumour lesions [26].
These data suggest that [18F]DOPA PET scanning
is superior to the somatostatin scan in neuroendocrine
patients with regard to localisation of tumour lesions.
HER2 imaging
The combination of the antibody trastuzumab directed
against the HER2 growth factor receptor and chemother-
apy can induce remissions but also cardiac dysfunction
in HER2-positive metastatic breast cancer. We evaluated
whether radiolabelled trastuzumab scintigraphy can pre-
dict cardiotoxicity, tumour response, and identify tumour
lesions [27]. In an ongoing study, patients with HER2
positive metastatic breast cancer, suitable for trastuzumab
and paclitaxel, underwent gamma camera imaging after
injection of 150 MBq of [111In]DTPA-trastuzumab, prior
to and after four therapy cycles. In known tumour
lesions (CT, ultrasound, X-ray, bone scan), the degree of
[111In]DTPA-trastuzumab tumour uptake was expressed
as the tumour vs. background uptake intensity ratio (T/bg
ratio), and as % injected dose index (tumour vs. total body
(TB) counts). Seventeen patients have been enrolled.
Variable tumour uptake was present in all patients after
5 and 7 days, starting from day 1. The T/bg ratio was
2.1 (1.4–3.5), 0.6% TB (0.1–5.5) at day 1 and 1.9 (1.3–
9.3), 0.7% TB (0.2–5.5) at day 7 after injection. One or
more lesions were visualised in each patient, although
not all known lesions. Previously unknown lesions were
found in seven patients. Liver metastases were difficult to
visualise due to high liver uptake. One patient with pre-
existing cardiac arrhythmias showed myocardial uptake.
We showed that radiolabelled trastuzumab scintigraphy
can identify HER2 positive lesions and may assist in
identifying metastases and predicting response. Defining
a predictive value for cardiotoxicity and tumour response
requires more patients. This study continues to recruit.
In the future, the precise role for HER2 imaging in
patients regarding tumour detection and prediction of
cardiotoxicity has to be established. It is also not yet clear
whether labelling of the whole antibody trastuzumab
for SPECT scanning or labelling of fragments of the
antibody, such as the diabodies for PET imaging, will be
preferable in the future [28].
Conclusions
Molecular imaging of tumours is still in its infancy.
The increasing elucidation of molecular determinants of
cancer and the wealth of molecular targeted drugs that are
coming into clinical oncological practice make molecular
tumour imaging a great challenge for the future. The
hope is that apart from tumour staging, it will be used
increasingly for early response prediction.
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